Drug Trial Radar · NCT07943533
HLX22 Combination Therapy in HER2-Positive Limited Metastatic Gastric Cancer
Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
30
Planned (sponsor's estimate)
Start
Dec 1, 2026
Primary completion
Dec 31, 2027
Study completion Dec 31, 2029
Sponsor
- Lead sponsor
- Shanghai Zhongshan HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Nov 17, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a prospective, open-label, exploratory study evaluating the efficacy and safety of HLX22 in combination with first-line systemic therapy in patients with HER2-positive, limited metastatic, unresectable gastric or gastroesophageal junction adenocarcinoma. Patients will receive HLX22 combined with trastuzumab and XELOX chemotherapy, with or without the PD-1 inhibitor HLX10 according to PD-L1 and mismatch repair status. The primary endpoint is objective response rate assessed by RECIST v1.1.
Conditions
- HER2-Positive
- Limited Metastatic
- Gastric Cancer
Interventions
HLX22Drug
HLX22 is administered intravenously every 3 weeks in combination with standard first-line systemic therapy, according to the protocol.
TrastuzumabDrug
Trastuzumab is administered intravenously in combination with HLX22 and chemotherapy. A loading dose of 8 mg/kg is given at the first administration, followed by maintenance doses of 6 mg/kg every 3 weeks.
XELOX ChemotherapyDrug
XELOX chemotherapy consists of:Oxaliplatin administered intravenously on Day 1 of each 3-week cycle;Capecitabine administered orally twice daily on Days 1-14 of each 3-week cycle.
HLX10Drug
HLX10, a PD-1 inhibitor, is administered intravenously every 3 weeks in participants assigned to the CPS ≥5 or dMMR arm, according to the study protocol.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response RateTime frame: From the start of study treatment to the first tumor response assessment after 4 cycles (each cycle is 21 days; approximately 12 weeks), or up to 6 cycles (approximately 18 weeks) for participants receiving extended treatment.
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.